EPS for RedHill Biopharma Ltd – ADR (RDHL) Expected At $-0.67

July 17, 2017 - By Louis Casey

 EPS for RedHill Biopharma Ltd   ADR (RDHL) Expected At $ 0.67

Investors wait RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) to report on July, 25. its quarterly earnings Wall Street analysts expect $-0.67 earnings per share, down $0.07 or 11.67 % from last year’s $-0.6 same quarter earnings. RedHill Biopharma Ltd – ADR’s Wall Street analysts see 34.00 % negative EPS growth, taking into account the $-0.50 EPS reproted in the previous quarter, About 69,963 shares traded. RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) has declined 9.09% since July 17, 2016 and is downtrending. It has underperformed by 25.79% the S&P500.

RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) Ratings Coverage

Among 6 analysts covering RedHill Biopharma (NASDAQ:RDHL), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. RedHill Biopharma had 10 analyst reports since July 29, 2015 according to SRatingsIntel. TheStreet downgraded the shares of RDHL in report on Tuesday, August 25 to “Hold” rating. Northland Capital initiated the shares of RDHL in report on Tuesday, September 29 with “Buy” rating. The stock of RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) has “Buy” rating given on Thursday, June 15 by FBR Capital. The rating was initiated by Nomura on Tuesday, September 29 with “Buy”. The stock has “Outperform” rating by FBR Capital on Friday, February 24. The company was upgraded on Saturday, August 22 by Zacks. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, June 15 report. TH Capital maintained the stock with “Buy” rating in Wednesday, July 29 report.

Redhill Biopharma Ltd, is an Israel specialty biopharmaceutical company. The company has market cap of $151.22 million. The Firm focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It currently has negative earnings. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Another recent and important RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) news was published by Benzinga.com which published an article titled: “Exclusive: RedHill Biopharma CEO Talks Steering His Company Through A Year …” on June 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.